

# Diabetic Retinopathy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/D8A40E0402EEN.html>

Date: May 2020

Pages: 324

Price: US\$ 2,000.00 (Single User License)

ID: D8A40E0402EEN

## Abstracts

Diabetic Retinopathy - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2020, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders)

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number

of Products under Development by Companies, H1 2020 The guide covers therapeutics under Development by Companies/Universities/Institutes,

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

Number of Products under Development for Diabetic Retinopathy, H1 2020 20Number of Products under Development by Companies, H1 2020 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



## Contents

Introduction

Diabetic Retinopathy - Overview

Diabetic Retinopathy - Therapeutics Development

Diabetic Retinopathy - Therapeutics Assessment

Diabetic Retinopathy - Companies Involved in Therapeutics Development

Diabetic Retinopathy - Drug Profiles

Diabetic Retinopathy - Dormant Projects

Diabetic Retinopathy - Discontinued Products

Diabetic Retinopathy - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Diabetic Retinopathy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Products under Development by Companies, H1 2020 (Contd..5), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Diabetic Retinopathy - Pipeline by 3SBio Inc, H1 2020  
Diabetic Retinopathy - Pipeline by A6 Pharmaceuticals LLC, H1 2020  
Diabetic Retinopathy - Pipeline by Accutis Pharmaceuticals Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Adverum Biotechnologies Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Afecta Pharmaceuticals Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Akaal Pharma Pty Ltd, H1 2020  
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Ltd, H1 2020  
Diabetic Retinopathy - Pipeline by Apexian Pharmaceuticals Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Applied Therapeutics Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Aptabio Therapeutics Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Aptamer Sciences Inc, H1 2020  
Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals Inc, H1 2020

Diabetic Retinopathy - Pipeline by Ascentage Pharma Group International, H1 2020

Diabetic Retinopathy - Pipeline by BetaStem Therapeutics Inc, H1 2020

Diabetic Retinopathy - Pipeline by Bio-Thera Solutions Ltd, H1 2020

Diabetic Retinopathy - Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..1), H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..2), H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..3), H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..4), H1 2020

Diabetic Retinopathy - Dormant Projects, H1 2020 (Contd..5), H1 2020

Diabetic Retinopathy - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Diabetic Retinopathy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

3SBio Inc  
A6 Pharmaceuticals LLC  
Accutis Pharmaceuticals Inc  
Adverum Biotechnologies Inc  
Aerie Pharmaceuticals Inc  
Afecta Pharmaceuticals Inc  
Akaal Pharma Pty Ltd  
Antisense Therapeutics Ltd  
Apexian Pharmaceuticals Inc  
Applied Therapeutics Inc  
AptaBio Therapeutics Inc  
Aptamer Sciences Inc  
Araim Pharmaceuticals Inc  
Ascentage Pharma Group International  
BetaStem Therapeutics Inc  
Bio-Thera Solutions Ltd  
Boehringer Ingelheim International GmbH  
Bonac Corp  
CCRP Therapeutics GmbH  
Cell Care Therapeutics Inc  
Charlesson LLC



Clayton Biotechnologies Inc  
Coherus BioSciences Inc  
Curacle Co Ltd  
Dimerix Ltd  
Elasmogen Ltd  
Emerald Bioscience Inc  
Ennovabio  
Epigen Biosciences Inc  
Everglades Biopharma LLC  
Excitant Therapeutics LLC  
EyePoint Pharmaceuticals Inc  
F. Hoffmann-La Roche Ltd  
Foresee Pharmaceuticals Co Ltd  
Formycon AG  
Generium  
Glycadia Inc  
Guangzhou Magpie Pharmaceutical Co Ltd  
Hana Pharm Co Ltd  
HanAll Biopharma Co Ltd  
Hengenix Biotech Inc  
iVeena Delivery Systems Inc  
Kato Pharmaceuticals Inc  
Kodiak Sciences Inc  
Kowa Co Ltd  
Kubota Vision Inc  
Kuur Therapeutics Ltd  
Lupin Ltd  
Luye Pharma Group Ltd  
Mabion SA  
Mirae Cell Bio Co Ltd  
Mirrx Therapeutics A/S  
Nanoscope Therapeutics Inc  
NeuMedics Inc  
Neurodegeneration Therapeutics Inc  
NGM Biopharmaceuticals Inc  
Novartis AG  
Novelty Nobility Inc  
Noveome Biotherapeutics Inc  
OccuRx Pty Ltd

Ocugen Inc  
OcuNexus Therapeutics Inc  
OliPass Corporation  
Opera Therapeutics  
Oxurion NV  
Palatin Technologies Inc  
Panoptes Pharma GesmbH  
Phanes Therapeutics Inc  
PharmAbcine Inc  
Profarma  
Protheragen Inc  
Regeneron Pharmaceuticals Inc  
RegenxBio Inc  
Retinset SL  
Retrotope Inc  
Reven Pharmaceuticals Inc  
Rezolute Inc  
Serodus ASA  
Singh Biotechnology LLC  
SiNOPSEE Therapeutics Pte Ltd  
Skyran Biologics Inc  
Stealth BioTherapeutics Corp  
SunBio Inc  
Sylentis SAU  
Teraclon IDF SL  
Topadur Pharma AG  
Translatum Medicus Inc  
Valitor Inc  
VESSL Therapeutics Ltd  
Wntgen LLC  
Xbrane Biopharma AB  
YD Life Science Co  
Zih Yuan Tang Biotechnology Co Ltd

## I would like to order

Product name: Diabetic Retinopathy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/D8A40E0402EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D8A40E0402EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970